Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients

Updated data from the Phase III GALACTIC-HF study of omecamtiv mecarbil show it may be particularly useful in a more severe subgroup of heart failure patients.

The latest readout from Cytokinetics Inc. (NASDAQ:CYTK) and partners Amgen Inc. (NASDAQ:AMGN) and Servier follows an Oct. 8 report that the small molecule cardiac myosin activator omecamtiv mecarbil produced a statistically significant reduction in time to cardiovascular death or first heart failure event (p=0.025) in the Phase III GALACTIC-HF trial. But the effect size — an 8% reduction — coupled with a miss on the secondary endpoint of reduction in time to CV death alone, suggested the primary outcome was driven by a small improvement in time to first heart failure event...